EICHORCondition: Alzheimer Disease · Sponsor: Eli Lilly and Company
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up to 332 weeks. Approximately 800 additional participants will be enrolled in the 12-month Addendum 7 to assess safety of a different titration regimen.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Parkway Medical Center | Birmingham, Alabama, United States | — |
| Alabama Psychiatry - Birmingham - Brookwood Medical Center Drive | Homewood, Alabama, United States | — |
| Rehabilitation & Neurological Services | Huntsville, Alabama, United States | — |
| Care Access - 801 South Power Road, Mesa | Mesa, Arizona, United States | — |
| Banner Alzheimer's Institute | Phoenix, Arizona, United States | — |
| Banner Alzheimer's Institute Tucson | Tucson, Arizona, United States | — |
| Center for Neurosciences | Tucson, Arizona, United States | — |
| Care Access - Berkeley | Berkeley, California, United States | — |
| Care Access - Beverly Hills | Beverly Hills, California, United States | — |
| Velocity Clinical Research, Chula Vista | Chula Vista, California, United States | — |
| Valley Clinical Trials, Inc. | Covina, California, United States | — |
| Neurology Center of North Orange County | Fullerton, California, United States | — |
+ 204 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05026866